Promising Phase 3 Data Could Propel Candel Therapeutics
AI Prediction of Candel Therapeutics, Inc. (CADL)
Candel Therapeutics is poised for potential growth with upcoming clinical and regulatory catalysts that could significantly influence its stock price.
Candel Therapeutics, a clinical-stage biopharmaceutical company, is focused on developing viral immunotherapies for cancer treatment. Its lead assets, aglatimagene besadenovec and linoserpaturev, target various cancers including prostate cancer and NSCLC. Key upcoming catalysts include the presentation of Phase 3 prostate cancer data and initiation of a Phase 3 trial for NSCLC. These events, coupled with a strengthened balance sheet and recent financial maneuvers to secure funding into Q1 2028, position the company in a potentially advantageous market position. Successful outcomes in these trials could lead to significant price movement due to the high unmet medical needs and substantial market sizes of the targeted indications.
CADL Report Information
Prediction Date2026-03-18
Close @ Prediction$5.17
Mkt Cap706m
IPO DateN/a
AI-derived Information
Recent News for CADL
- Jul 8, 4:05 pm — Candel Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire RSS)
- Jul 1, 4:05 pm — Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire RSS)
- Jun 30, 12:27 pm — CADL Stock Heads For Biggest Monthly Gains Since December 2024 Retail Says Our SLS Days Are Coming (Stocktwits)
- Jun 30, 9:07 am — New Human Study in Nature's Scientific Reports Finds Candela's Nordlys® Non-Ablative Fractional Laser Reverses the Skin's Epigenetic Signature of Aging (PRNewswire RSS)
- Jun 30, 8:05 am — Candel Therapeutics Announces Initiation of Global Pivotal Phase 3 AURORA Trial Evaluating Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors (GlobeNewswire RSS)
- Jun 25, 3:53 pm — Candel Therapeutics Designates Mark Sims as CCO (Exec Edge)
- Jun 25, 8:05 am — Candel Therapeutics Appoints Mark Sims as Chief Commercial Officer (GlobeNewswire RSS)
- Jun 22, 9:01 am — CANDELA BRINGS GLACĒ™, THE NEXT-LEVEL FACIAL, ON A NATIONAL SUMMER TOUR TO DELIVER "GLASS SKIN" GLOW TO YOUR AREA, WITH GUEST APPEARANCES FROM BRIGETTE PHELOUNG AND DR. DENDY ENGELMAN (PRNewswire RSS)
- Jun 16, 4:23 pm — CADL SEC filing points to financing activity (ScanScor Filing Bot)
- Jun 5, 6:23 am — CADL Stock Heads For Best Week In A Month Heres Why Retail Is Bullish (Stocktwits)
- Jun 2, 8:05 am — Candel Therapeutics Announces Publication in The Lancet Oncology of Pivotal Phase 3 Data Demonstrating Significant Improvement in Disease-Free Survival with Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer (GlobeNewswire RSS)
- Jun 1, 4:05 pm — Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire RSS)
Welcome to ScanScor. What you're reading is no ordinary summary -- it's the result of a carefully-crafted interactive session with OpenAI's most advanced models crafted from news, trial details, and financial data. This report attempts to maximize the potential for OpenAI's smartest GPT-based analysis engine, guided by tightly structured prompts to expose the forces behind today's market movers and to predict the future.
Disclaimer: This report is for informational purposes only. It does not constitute financial advice. Always do your own research before making any investment.
Subscribe
Login
Please login to comment
0 Comments
Oldest